Wang Li, Qin Xianfei, Zhang Yu, Xue Shouyu, Song Xicheng
Otorhinolaryngology Head and Neck Surgery, Yantai Yuhuangding Hospital, Yantai Shandong, China.
School of Clinical Medicine, Binzhou Medical University, Yantai, China.
Front Oncol. 2023 Feb 3;13:1006233. doi: 10.3389/fonc.2023.1006233. eCollection 2023.
To study the predictive value of systemic immune index (SII) and systemic inflammatory response index (SIRI) in the prognosis of patients with nasopharyngeal carcinoma.
Two researchers independently searched PubMed, Cochrane, Embase, and Web of Science databases (until March 18, 2022) for all studies on SII, SIRI, and prognosis in patients with nasopharyngeal carcinoma. Quality assessment of included studies was assessed using the Newcastle-Ottawa Scale (NOS). In addition, a bivariate mixed-effects model was used to explore predictive value.
A total of 9 studies that satisfied the requirements were included, involving, 3187 patients with nasopharyngeal carcinoma. The results of the meta-analysis showed that SII could be an independent predictor of OS (HR=1.78, 95%CI [1.44-2.20], Z=5.28, P<0.05), and SII could also be an independent predictor of PFS (HR=1.66, 95%CI [1.36-2.03], Z=4.94, P<0.05). In addition, SIRI could also serve as an independent predictor of OS (HR=2.88, 95%CI [1.97-4.19], Z=5.51, P<0.05). The ROC area was 0.63, the sensitivity was 0.68 (95%CI [0.55-0.78]), and the specificity was 0.55 (95%CI [0.47-0.62]), all of which indicated that SII had a certain predictive value for OS.
SII and SIRI can be used as independent predictors to predict the prognosis and survival status of patients with nasopharyngeal carcinoma and have certain predictive accuracy. Therefore, SII and SIRI should be considered in studies that update survival risk assessment systems.
https://www.ytyhdyy.com/, identifier PROSPERO (CRD42022319678).
探讨全身免疫指数（SII）和全身炎症反应指数（SIRI）对鼻咽癌患者预后的预测价值。
两名研究人员独立检索PubMed、Cochrane、Embase和Web of Science数据库（截至2022年3月18日），查找所有关于SII、SIRI与鼻咽癌患者预后的研究。采用纽卡斯尔-渥太华量表（NOS）对纳入研究进行质量评估。此外，使用双变量混合效应模型探讨预测价值。
共纳入9项符合要求的研究，涉及3187例鼻咽癌患者。荟萃分析结果显示，SII可作为总生存期（OS）的独立预测因子（HR=1.78，95%CI[1.44-2.20]，Z=5.28，P<0.05），SII也可作为无进展生存期（PFS）的独立预测因子（HR=1.66，95%CI[1.36-2.03]，Z=4.94，P<0.05）。此外，SIRI也可作为OS的独立预测因子（HR=2.88，95%CI[1.97-4.19]，Z=5.51，P<0.05）。ROC曲线下面积为0.63，灵敏度为0.68（95%CI[0.55-0.78]），特异度为0.55（95%CI[0.47-0.62]），均表明SII对OS具有一定的预测价值。
SII和SIRI可作为独立预测因子，用于预测鼻咽癌患者的预后和生存状况，且具有一定的预测准确性。因此，在更新生存风险评估系统的研究中应考虑SII和SIRI。
